|
GB8712540D0
(en)
|
1987-05-28 |
1987-07-01 |
Ucb Sa |
Expression of human proapolipoprotein a-i
|
|
US5220043A
(en)
|
1991-03-21 |
1993-06-15 |
Ohio University |
Synthesis of D-erythro-sphingomyelins
|
|
SE9103701D0
(sv)
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
SE9203753D0
(sv)
|
1992-12-11 |
1992-12-11 |
Kabi Pharmacia Ab |
Expression system for producing apolipoprotein ai-m
|
|
FR2704556B1
(fr)
|
1993-04-30 |
1995-07-13 |
Rhone Poulenc Rorer Sa |
Virus recombinants et leur utilisation en thérapie génique.
|
|
JP3754072B2
(ja)
|
1994-03-22 |
2006-03-08 |
リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド |
摂食抑制ペプチド
|
|
US5932536A
(en)
|
1994-06-14 |
1999-08-03 |
The Rockefeller University |
Compositions for neutralization of lipopolysaccharides
|
|
SE9500778D0
(sv)
|
1995-03-03 |
1995-03-03 |
Pharmacia Ab |
Process for producing a protein
|
|
US5648387A
(en)
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
US6258596B1
(en)
|
1995-05-22 |
2001-07-10 |
Aventis Pharmaceuticals Products Inc. |
Variants of apolipoprotein A-I
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
SE9603068D0
(sv)
|
1996-08-23 |
1996-08-23 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
SE9603303D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
SE9603304D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a compound
|
|
US6306433B1
(en)
|
1997-08-12 |
2001-10-23 |
Pharmacia Ab |
Method of preparing pharmaceutical compositions
|
|
US6518412B1
(en)
|
1997-09-29 |
2003-02-11 |
Jean-Louis Dasseux |
Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
ATE266672T1
(de)
|
1998-12-30 |
2004-05-15 |
Folke Tjerneld |
Trennungsmethode unter verwendung von flüssig- flüssig partition
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
GB9919713D0
(en)
|
1999-08-19 |
1999-10-20 |
Queen Mary & Westfield College |
New medical use of high density lipoprotein
|
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP2206720A1
(en)
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2001257173B2
(en)
|
2000-04-21 |
2005-09-22 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US7144862B2
(en)
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7723303B2
(en)
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
MXPA03003024A
(es)
|
2000-10-11 |
2003-07-14 |
Esperion Therapeutics Inc |
Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados.
|
|
IL155215A0
(en)
|
2000-10-11 |
2003-11-23 |
Esperion Therapeutics Inc |
Ether compounds and compositions for cholesterol management and related uses
|
|
WO2002030860A2
(en)
|
2000-10-11 |
2002-04-18 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
AU2002211666A1
(en)
|
2000-10-11 |
2002-04-22 |
Esperion Therapeutics, Inc. |
Sulfide and disulfide compounds and compositions for cholesterol management and related uses
|
|
US7304093B2
(en)
|
2000-10-11 |
2007-12-04 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
EP2343317A1
(en)
|
2000-11-10 |
2011-07-13 |
F. Hoffmann-La Roche Ltd. |
Apolipoprotein analogues
|
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US6991727B2
(en)
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
WO2003000381A1
(en)
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
CA2457840C
(en)
|
2001-08-20 |
2011-10-11 |
Zlb Bioplasma Ag |
Hdl for the treatment of stroke and other ischemic conditions
|
|
AU2002362612B2
(en)
|
2001-09-28 |
2007-11-15 |
Cedars-Sinai Medical Center |
Prevention and treatment of restenosis by local administration of drug
|
|
AUPR798901A0
(en)
|
2001-09-28 |
2001-10-25 |
Medvet Science Pty. Ltd. |
Spheroidal hdl particles with a defined phospholipid composition
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
US7223726B2
(en)
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
AU2003239489A1
(en)
|
2002-05-17 |
2003-12-02 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
|
EP1545576A2
(en)
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
HUE036646T2
(hu)
|
2003-01-23 |
2018-07-30 |
Esperion Therapeutics Inc |
Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
|
|
DK1641421T3
(en)
|
2003-07-03 |
2019-03-11 |
Hdl Therapeutics Inc |
Methods and apparatus for producing HDL particle derivatives of reduced lipid content
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
ATE428411T1
(de)
|
2003-11-07 |
2009-05-15 |
Jj Pharma Inc |
Hdl-verstärkende kombinationstherapie-komplexe
|
|
TW200526778A
(en)
|
2003-11-14 |
2005-08-16 |
Sembiosys Genetics Inc |
Methods for the production of apolipoproteins in transgenic plants
|
|
EP2306192B1
(en)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risk Markers For Cardiovascular Disease
|
|
WO2005058938A2
(en)
|
2003-12-15 |
2005-06-30 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
JP2007525408A
(ja)
|
2003-12-24 |
2007-09-06 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロール管理および関連使用のためのケトン化合物および組成物
|
|
KR100560102B1
(ko)
|
2004-06-25 |
2006-03-13 |
한국생명공학연구원 |
프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
|
|
US7378396B2
(en)
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
ATE469174T1
(de)
|
2004-10-15 |
2010-06-15 |
Us Gov Health & Human Serv |
Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
CA2653840A1
(en)
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
|
|
WO2008021088A2
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
US8541236B2
(en)
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
WO2008092231A1
(en)
|
2007-02-01 |
2008-08-07 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular diseases
|
|
US7956035B2
(en)
|
2007-03-01 |
2011-06-07 |
Csl Limited |
Treatment of endothelial dysfunction in diabetic patients
|
|
US7749315B2
(en)
|
2007-04-04 |
2010-07-06 |
Xerox Corporation |
Phase change inks containing colorant compounds
|
|
EP2522674A1
(en)
|
2007-08-17 |
2012-11-14 |
CSL Behring GmbH |
Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
WO2009050275A1
(en)
|
2007-10-19 |
2009-04-23 |
Pronota N.V. |
A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications
|
|
EA201070517A1
(ru)
|
2007-10-23 |
2010-12-30 |
Дзе Кливленд Клиник Фаундейшн |
Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
|
|
CN102123722A
(zh)
|
2008-06-18 |
2011-07-13 |
加利福尼亚大学董事会 |
改进的胆固醇流出的肽介质
|
|
LT2939683T
(lt)
|
2009-02-16 |
2017-03-27 |
Cerenis Therapeutics Holding Sa |
Apolipoproteino a-i mimetikai
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
US20110152112A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Artery Therapeutics, Inc. |
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
|
|
MX2012014928A
(es)
|
2010-06-30 |
2013-03-22 |
Csl Ltd |
Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
|
|
EP2673296B1
(en)
|
2011-02-07 |
2018-10-24 |
Cerenis Therapeutics Holding SA |
Lipoprotein complexes and manufacturing and uses thereof
|